Denali Therapeutics Inc Stock

Do the numbers hold clues to what lies ahead for the stock? Enter the amount you'd like to invest in denali therapeutics inc stock, then proceed to checkout.

Denali Therapeutics Announces Closing Of Collaboration

During the last session, denali therapeutics inc.

Denali therapeutics inc stock. Shares of denali therapeutics inc. 11 rows find out the direct holders, institutional holders and mutual fund holders for denali. The stock had previously closed at $54.10, but opened at $50.71.

This suggests a possible upside of 98.0% from the stock's current price. The sale was disclosed in a legal filing with the securities & exchange commission, which can be accessed through this link. (dnli) reports q2 loss, lags revenue estimates.

The company is focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer's disease, parkinson's disease, amyotrophic lateral sclerosis (als) and others. 8 brokerages have issued 1 year target prices for denali therapeutics' shares. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable.

(nasdaq:dnli) price on friday, november 19, rose 0.11% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $47.11. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than. Denali therapeutics started at outperform with $85 stock price target at oppenheimer.

(dnli) came out with a quarterly loss of $0.69 per share versus the zacks consensus estimate of a loss of $0.51. Their forecasts range from $70.00 to $111.00. Denali is applying deep scientific and drug development expertise to fully harvest the potential of these pathways in order to discover effective molecular therapeutics.

The shares were sold at an average price of $44.92, for a total transaction of $823,518.36. Is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. (nasdaq:dnli)’s traded shares were 0.33 million, with the beta value of the company hitting 1.76.

How to buy denali therapeutics inc stock on stash. At the end of the trading day, the stock’s price was $47.64, reflecting an intraday gain of 2.65% or $1.23. On average, they expect denali therapeutics' stock price to reach $93.29 in the next year.

Dnli | complete denali therapeutics inc. Denali therapeutics shares last traded at $52.87, with a. It is hard to get excited after looking at denali therapeutics' (nasdaq:dnli) recent performance, when its stock has declined 7.9% over the past week.

Oppenheimer has initiated shares of denali therapeutics with a buy rating saying the company is an underappreciated emerging leader in neurodegeneration and cns disorders. (nasdaq:dnli) shares, rose in value on friday, 11/05/21, with the stock price up by 4.44% to the previous day’s close as strong demand from buyers drove the stock to $55.02. Actively observing the price movement in the last trading, the stock closed the session at $52.68,

(nasdaq:dnli) gapped down prior to trading on tuesday after an insider sold shares in the company. Watts sold 18,333 shares of the firm's stock in a transaction that occurred on wednesday, december 1st. A look at the stock’s price movement, the close in the last trading session was $47.06, moving within a range at $46.48 and $48.27.